Advertisement


Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Advertisement